The addition of trastuzumab to adjuvant chemotherapy dramatically improved both disease-free survival (DFS) and OS as compared with chemotherapy alone in patients with HER2+ EBC [110], and this regimen is currently approved in patients with HER2+ node-positive BC and in patients with node-negative disease and tumors >1 cm [6]. The gene discussed is ERBB2; the disease is breast cancer.